http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 10 Aug 2026 07:35:40 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Amgen+%28AMGN%29+PT+Raised+to+%24388+at+Guggenheim/26894360.html (Updated - August 10, 2026 7:35 AM EDT) <p>Guggenheim analyst Vamil Divan raised the price target on Amgen (NASDAQ: AMGN) to $388.00 (from $343.00) while maintaining a Neutral rating.</p><p>The analyst commented: "We are updating our AMGN model following the company's 2Q 2026 earnings release last Tuesday. The company reported an impressive quarter and provided updated FY 2026 guidance, which was above our and Consensus expectations. We revise our model to account for the quarterly results and business updates, leading to a meaningful increase in our FY 2026 revenue estimate to $38.85B (from $37.49B) and an increase in our FY 2026 non-GAAP http://www.streetinsider.com/Analyst+PT+Change/Amgen+%28AMGN%29+PT+Raised+to+%24388+at+Guggenheim/26894360.html Mon, 10 Aug 2026 07:35:40 -0400 AMGN http://www.streetinsider.com/Analyst+Comments/Amgen+%28AMGN%29+PT+Raised+to+%24388+at+Guggenheim/26894360.html (Updated - August 10, 2026 7:35 AM EDT) <p>Guggenheim analyst Vamil Divan raised the price target on Amgen (NASDAQ: AMGN) to $388.00 (from $343.00) while maintaining a Neutral rating.</p><p>The analyst commented: "We are updating our AMGN model following the company's 2Q 2026 earnings release last Tuesday. The company reported an impressive quarter and provided updated FY 2026 guidance, which was above our and Consensus expectations. We revise our model to account for the quarterly results and business updates, leading to a meaningful increase in our FY 2026 revenue estimate to $38.85B (from $37.49B) and an increase in our FY 2026 non-GAAP http://www.streetinsider.com/Analyst+Comments/Amgen+%28AMGN%29+PT+Raised+to+%24388+at+Guggenheim/26894360.html Mon, 10 Aug 2026 07:35:40 -0400 AMGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AMGEN+INC+++++++++++++++++For%3A+Aug+06++Filed+by%3A+Miller+Derek/26892447.html si-local-file:///var/storage/secattach/20260807/26892447.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AMGEN+INC+++++++++++++++++For%3A+Aug+06++Filed+by%3A+Miller+Derek/26892447.html Fri, 07 Aug 2026 18:47:00 -0400 AMGN O.00027089 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AMGEN+INC+++++++++++++++++For%3A+Aug+06++Filed+by%3A+Miller+Derek/26892447.html si-local-file:///var/storage/secattach/20260807/26892447.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AMGEN+INC+++++++++++++++++For%3A+Aug+06++Filed+by%3A+Miller+Derek/26892447.html Fri, 07 Aug 2026 18:47:00 -0400 AMGN O.00027089 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AMGEN+INC+++++++++++++++++For%3A+Aug+06++Filed+by%3A+Grygiel+Nancy+A./26892446.html si-local-file:///var/storage/secattach/20260807/26892446.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AMGEN+INC+++++++++++++++++For%3A+Aug+06++Filed+by%3A+Grygiel+Nancy+A./26892446.html Fri, 07 Aug 2026 18:46:00 -0400 AMGN O.00027089 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AMGEN+INC+++++++++++++++++For%3A+Aug+06++Filed+by%3A+Grygiel+Nancy+A./26892446.html si-local-file:///var/storage/secattach/20260807/26892446.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AMGEN+INC+++++++++++++++++For%3A+Aug+06++Filed+by%3A+Grygiel+Nancy+A./26892446.html Fri, 07 Aug 2026 18:46:00 -0400 AMGN O.00027089 http://www.streetinsider.com/General+News/Morgan+Stanley+tracks+US+drug+market+prescriptions+for+week+ending+July+31/26889641.html <p>Investing.com -- Morgan Stanley released its weekly analysis of US prescription drug market data for the week ending July 31, showing total prescription year-over-year growth of 1.5% compared to 2.0% the previous week and 1.3% over the past 12 weeks.</p><p>The rolling 4-week total prescription year-over-year change was -0.2%, while the rolling 12-week total prescription year-over-year change was 1.3%. Extended unit weekly year-over-year growth was 1.1%, below total prescription year-over-year growth. Sequential weekly total prescription growth was -0.5% compared to -0.4% the week before.</p><p>Bristol-Myers Squibb's (NYSE:BMY) Cobenfy, approved for schizophrenia on September 26, 2024, recorded approximately 3,370 scripts for the week http://www.streetinsider.com/General+News/Morgan+Stanley+tracks+US+drug+market+prescriptions+for+week+ending+July+31/26889641.html Fri, 07 Aug 2026 12:04:12 -0400 AMGN BMY GILD JNJ VRTX http://www.streetinsider.com/General+News/Morgan+Stanley+tracks+US+drug+market+prescriptions+for+week+ending+July+31/26889641.html <p>Investing.com -- Morgan Stanley released its weekly analysis of US prescription drug market data for the week ending July 31, showing total prescription year-over-year growth of 1.5% compared to 2.0% the previous week and 1.3% over the past 12 weeks.</p><p>The rolling 4-week total prescription year-over-year change was -0.2%, while the rolling 12-week total prescription year-over-year change was 1.3%. Extended unit weekly year-over-year growth was 1.1%, below total prescription year-over-year growth. Sequential weekly total prescription growth was -0.5% compared to -0.4% the week before.</p><p>Bristol-Myers Squibb's (NYSE:BMY) Cobenfy, approved for schizophrenia on September 26, 2024, recorded approximately 3,370 scripts for the week http://www.streetinsider.com/General+News/Morgan+Stanley+tracks+US+drug+market+prescriptions+for+week+ending+July+31/26889641.html Fri, 07 Aug 2026 12:04:12 -0400 AMGN BMY GILD JNJ VRTX http://www.streetinsider.com/General+News/Morgan+Stanley+tracks+US+drug+market+prescriptions+for+week+ending+July+31/26889641.html <p>Investing.com -- Morgan Stanley released its weekly analysis of US prescription drug market data for the week ending July 31, showing total prescription year-over-year growth of 1.5% compared to 2.0% the previous week and 1.3% over the past 12 weeks.</p><p>The rolling 4-week total prescription year-over-year change was -0.2%, while the rolling 12-week total prescription year-over-year change was 1.3%. Extended unit weekly year-over-year growth was 1.1%, below total prescription year-over-year growth. Sequential weekly total prescription growth was -0.5% compared to -0.4% the week before.</p><p>Bristol-Myers Squibb's (NYSE:BMY) Cobenfy, approved for schizophrenia on September 26, 2024, recorded approximately 3,370 scripts for the week http://www.streetinsider.com/General+News/Morgan+Stanley+tracks+US+drug+market+prescriptions+for+week+ending+July+31/26889641.html Fri, 07 Aug 2026 12:04:12 -0400 AMGN BMY GILD JNJ VRTX http://www.streetinsider.com/General+News/Morgan+Stanley+tracks+US+drug+market+prescriptions+for+week+ending+July+31/26889641.html <p>Investing.com -- Morgan Stanley released its weekly analysis of US prescription drug market data for the week ending July 31, showing total prescription year-over-year growth of 1.5% compared to 2.0% the previous week and 1.3% over the past 12 weeks.</p><p>The rolling 4-week total prescription year-over-year change was -0.2%, while the rolling 12-week total prescription year-over-year change was 1.3%. Extended unit weekly year-over-year growth was 1.1%, below total prescription year-over-year growth. Sequential weekly total prescription growth was -0.5% compared to -0.4% the week before.</p><p>Bristol-Myers Squibb's (NYSE:BMY) Cobenfy, approved for schizophrenia on September 26, 2024, recorded approximately 3,370 scripts for the week http://www.streetinsider.com/General+News/Morgan+Stanley+tracks+US+drug+market+prescriptions+for+week+ending+July+31/26889641.html Fri, 07 Aug 2026 12:04:12 -0400 AMGN BMY GILD JNJ VRTX http://www.streetinsider.com/General+News/Morgan+Stanley+tracks+US+drug+market+prescriptions+for+week+ending+July+31/26889641.html <p>Investing.com -- Morgan Stanley released its weekly analysis of US prescription drug market data for the week ending July 31, showing total prescription year-over-year growth of 1.5% compared to 2.0% the previous week and 1.3% over the past 12 weeks.</p><p>The rolling 4-week total prescription year-over-year change was -0.2%, while the rolling 12-week total prescription year-over-year change was 1.3%. Extended unit weekly year-over-year growth was 1.1%, below total prescription year-over-year growth. Sequential weekly total prescription growth was -0.5% compared to -0.4% the week before.</p><p>Bristol-Myers Squibb's (NYSE:BMY) Cobenfy, approved for schizophrenia on September 26, 2024, recorded approximately 3,370 scripts for the week http://www.streetinsider.com/General+News/Morgan+Stanley+tracks+US+drug+market+prescriptions+for+week+ending+July+31/26889641.html Fri, 07 Aug 2026 12:04:12 -0400 AMGN BMY GILD JNJ VRTX http://www.streetinsider.com/SEC+Filings/Form++144++++++++AMGEN+INC++++++++++++++++++++++++++++++Filed+by%3A+Miller+Derek/26885473.html si-local-file:///var/storage/secattach/20260806/26885473.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++AMGEN+INC++++++++++++++++++++++++++++++Filed+by%3A+Miller+Derek/26885473.html Thu, 06 Aug 2026 17:10:00 -0400 AMGN O.00027089 http://www.streetinsider.com/SEC+Filings/Form++144++++++++AMGEN+INC++++++++++++++++++++++++++++++Filed+by%3A+Miller+Derek/26885473.html si-local-file:///var/storage/secattach/20260806/26885473.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++AMGEN+INC++++++++++++++++++++++++++++++Filed+by%3A+Miller+Derek/26885473.html Thu, 06 Aug 2026 17:10:00 -0400 AMGN O.00027089 http://www.streetinsider.com/SEC+Filings/Form++144A++++++AMGEN+INC++++++++++++++++++++++++++++++Filed+by%3A+Grygiel+Nancy+A./26882994.html si-local-file:///var/storage/secattach/20260806/26882994.html http://www.streetinsider.com/SEC+Filings/Form++144A++++++AMGEN+INC++++++++++++++++++++++++++++++Filed+by%3A+Grygiel+Nancy+A./26882994.html Thu, 06 Aug 2026 15:17:00 -0400 AMGN O.00027089 http://www.streetinsider.com/SEC+Filings/Form++144A++++++AMGEN+INC++++++++++++++++++++++++++++++Filed+by%3A+Grygiel+Nancy+A./26882994.html si-local-file:///var/storage/secattach/20260806/26882994.html http://www.streetinsider.com/SEC+Filings/Form++144A++++++AMGEN+INC++++++++++++++++++++++++++++++Filed+by%3A+Grygiel+Nancy+A./26882994.html Thu, 06 Aug 2026 15:17:00 -0400 AMGN O.00027089 http://www.streetinsider.com/SEC+Filings/Form++144++++++++AMGEN+INC++++++++++++++++++++++++++++++Filed+by%3A+Grygiel+Nancy+A./26882608.html si-local-file:///var/storage/secattach/20260806/26882608.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++AMGEN+INC++++++++++++++++++++++++++++++Filed+by%3A+Grygiel+Nancy+A./26882608.html Thu, 06 Aug 2026 14:13:00 -0400 AMGN O.00027089 http://www.streetinsider.com/SEC+Filings/Form++144++++++++AMGEN+INC++++++++++++++++++++++++++++++Filed+by%3A+Grygiel+Nancy+A./26882608.html si-local-file:///var/storage/secattach/20260806/26882608.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++AMGEN+INC++++++++++++++++++++++++++++++Filed+by%3A+Grygiel+Nancy+A./26882608.html Thu, 06 Aug 2026 14:13:00 -0400 AMGN O.00027089 http://www.streetinsider.com/Analyst+PT+Change/Amgen+%28AMGN%29+PT+Raised+to+%24345+at+Bernstein+SocGen+Group/26880633.html Bernstein SocGen Group analyst Courtney Breen raised the price target on Amgen (NASDAQ: AMGN) to $345.00 (from $335.00) while maintaining a Market Perform rating. http://www.streetinsider.com/Analyst+PT+Change/Amgen+%28AMGN%29+PT+Raised+to+%24345+at+Bernstein+SocGen+Group/26880633.html Thu, 06 Aug 2026 09:24:43 -0400 AMGN http://www.streetinsider.com/Analyst+PT+Change/Amgen+%28AMGN%29+PT+Raised+to+%24452+at+TD+Cowen/26870707.html (Updated - August 5, 2026 9:53 AM EDT) <p>TD Cowen analyst Yaron Werber raised the price target on Amgen (NASDAQ: AMGN) to $452.00 (from $420.00) while maintaining a Buy rating.</p><p>The analyst commented: "Big Beats, Raised Guidance, And Key Ph3 Catalysts Ahead; Q2 beat-and-raise with revs/EPS $10.1B/$6.29 vs cons $9.4B/$5.60. FY26 revs/EPS guidance raised. Beats across growth & existing franchises show pipeline is offsetting LOEs and pricing pressure. Ph3 data for dazo in SjD, NVS/IONS Lp(a)HORIZON (H2:26), Teze EoE (Q4:26), MariTide in obesity (H1:27) support attractive setup into FY27. We raise PT to $452 (+$32), 18x FY27E EPS. Reiterate Buy."</p> http://www.streetinsider.com/Analyst+PT+Change/Amgen+%28AMGN%29+PT+Raised+to+%24452+at+TD+Cowen/26870707.html Wed, 05 Aug 2026 09:53:23 -0400 AMGN http://www.streetinsider.com/Analyst+Comments/Amgen+%28AMGN%29+PT+Raised+to+%24452+at+TD+Cowen/26870707.html (Updated - August 5, 2026 9:53 AM EDT) <p>TD Cowen analyst Yaron Werber raised the price target on Amgen (NASDAQ: AMGN) to $452.00 (from $420.00) while maintaining a Buy rating.</p><p>The analyst commented: "Big Beats, Raised Guidance, And Key Ph3 Catalysts Ahead; Q2 beat-and-raise with revs/EPS $10.1B/$6.29 vs cons $9.4B/$5.60. FY26 revs/EPS guidance raised. Beats across growth & existing franchises show pipeline is offsetting LOEs and pricing pressure. Ph3 data for dazo in SjD, NVS/IONS Lp(a)HORIZON (H2:26), Teze EoE (Q4:26), MariTide in obesity (H1:27) support attractive setup into FY27. We raise PT to $452 (+$32), 18x FY27E EPS. Reiterate Buy."</p> http://www.streetinsider.com/Analyst+Comments/Amgen+%28AMGN%29+PT+Raised+to+%24452+at+TD+Cowen/26870707.html Wed, 05 Aug 2026 09:53:23 -0400 AMGN http://www.streetinsider.com/Analyst+PT+Change/Amgen+%28AMGN%29+PT+Raised+to+%24400+at+RBC+Capital+After+an+%27Impressive+Q%27/26870382.html (Updated - August 5, 2026 9:18 AM EDT) <p>RBC Capital analyst Luca Issi raised the price target on Amgen (NASDAQ: AMGN) to $400.00 (from $370.00) while maintaining an Outperform rating.</p><p>The analyst commented: "Impressive Q For A Stock That Has Clear Momentum And Relatively Quiet Rest Of 2026; Quarter was a meaningful beat ($9.54b top-line vs $9.43b consensus) primarily driver by Repatha ($953m vs $921m consensus as uptake in high-risk primary prevention continues to gain momentum), Evenity ($714m vs $642m consensus and +38% Y/Y), Tepezza ($576m vs $544m consensus and 14% Y/Y) and Uplizna ($335m vs $222m consensus driven by uptake across http://www.streetinsider.com/Analyst+PT+Change/Amgen+%28AMGN%29+PT+Raised+to+%24400+at+RBC+Capital+After+an+%27Impressive+Q%27/26870382.html Wed, 05 Aug 2026 09:18:50 -0400 AMGN http://www.streetinsider.com/Analyst+Comments/Amgen+%28AMGN%29+PT+Raised+to+%24400+at+RBC+Capital+After+an+%27Impressive+Q%27/26870382.html (Updated - August 5, 2026 9:18 AM EDT) <p>RBC Capital analyst Luca Issi raised the price target on Amgen (NASDAQ: AMGN) to $400.00 (from $370.00) while maintaining an Outperform rating.</p><p>The analyst commented: "Impressive Q For A Stock That Has Clear Momentum And Relatively Quiet Rest Of 2026; Quarter was a meaningful beat ($9.54b top-line vs $9.43b consensus) primarily driver by Repatha ($953m vs $921m consensus as uptake in high-risk primary prevention continues to gain momentum), Evenity ($714m vs $642m consensus and +38% Y/Y), Tepezza ($576m vs $544m consensus and 14% Y/Y) and Uplizna ($335m vs $222m consensus driven by uptake across http://www.streetinsider.com/Analyst+Comments/Amgen+%28AMGN%29+PT+Raised+to+%24400+at+RBC+Capital+After+an+%27Impressive+Q%27/26870382.html Wed, 05 Aug 2026 09:18:50 -0400 AMGN http://www.streetinsider.com/Analyst+PT+Change/Amgen+%28AMGN%29+PT+Raised+to+%24440+at+UBS/26871033.html UBS analyst Michael Yee raised the price target on Amgen (NASDAQ: AMGN) to $440.00 (from $420.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Amgen+%28AMGN%29+PT+Raised+to+%24440+at+UBS/26871033.html Wed, 05 Aug 2026 08:54:35 -0400 AMGN http://www.streetinsider.com/Analyst+PT+Change/Amgen+%28AMGN%29+PT+Raised+to+%24400+at+Wells+Fargo/26870465.html Wells Fargo analyst Mohit Bansal raised the price target on Amgen (NASDAQ: AMGN) to $400.00 (from $390.00) while maintaining a Equal Weight rating. http://www.streetinsider.com/Analyst+PT+Change/Amgen+%28AMGN%29+PT+Raised+to+%24400+at+Wells+Fargo/26870465.html Wed, 05 Aug 2026 07:56:04 -0400 AMGN http://www.streetinsider.com/Analyst+PT+Change/Amgen+%28AMGN%29+PT+Raised+to+%24450+at+BMO+Capital/26870188.html BMO Capital analyst Evan David Seigerman raised the price target on Amgen (NASDAQ: AMGN) to $450.00 (from $400.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Amgen+%28AMGN%29+PT+Raised+to+%24450+at+BMO+Capital/26870188.html Wed, 05 Aug 2026 07:11:00 -0400 AMGN